Sanofi joins insulin price cap trend, cuts cost by 78%.

Sanofi, one of the top three insulin manufacturers for the U.S., announced it would be cutting the list price for its most prescribed insulin product Lantus by 78 percent, joining fellow major insulin manufacturers in drastically minimizing the prices of some of their insulin products. These price cuts will go into effect beginning on Jan. 1, 2024. The Biden administration has called for $35 price caps on insulin since a cap was included in the Inflation Reduction Act for Medicare beneficiaries.